Showing results (1811-1820 of 1,960) with videos related to
Sort By:
Pageof 196
Leukemia|March 7, 2020
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCLKeenan T Hartert, Kerstin Wenzl, Jordan E Krull, et al.Cell Reports. Medicine|March 1, 2024
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironmentsJordan E Krull, Kerstin Wenzl, Melissa A Hopper, et al.Circulation|April 22, 2018
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial FibrillationEmily C O'Brien, DaJuanicia N Holmes, Laine E Thomas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphomaCarrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.Blood|June 15, 2016
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphomaRebecca L Boddicker, Gina L Razidlo, Surendra Dasari, et al.American Heart Journal|December 11, 2017
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registriesBenjamin A Steinberg, Haiyan Gao, Peter Shrader, et al.European Journal of Haematology|March 3, 2021
Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucelMegan Melody, Sangeetha Gandhi, Zaid Abdel Rahman, et al.British Journal of Haematology|August 2, 2021
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.Pageof 196